Endo Pharmaceuticals Acquires Par Pharma

According to biospace.com, Endo Pharmaceuticals acquired Par Pharma for $8.05 billion. In the article, the CEO of Endo Pharmaceuticals says: “This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive...